Evidence Level
Pterostilbene is increasingly viewed as a practical upgrade over resveratrol due to its dramatically superior pharmacokinetics. Kapetanovic et al. (2011) established the favorable bioavailability profile, demonstrating that pterostilbene has better absorption and metabolic stability compared to resveratrol. Riche et al. (2014) published the most significant human trial, which found that pterostilbene supplementation led to a reduction in blood pressure and improved cardiovascular health markers. Additionally, Chang et al. (2012) showed cognitive benefits in aging animal models, indicating potential neuroprotective effects of pterostilbene.
Recent studies have further expanded the understanding of pterostilbene's benefits. Buehrer et al. (2026) conducted a systematic review of 13 studies and found that pterostilbene induces apoptosis and limits proliferation in multiple myeloma cell lines, suggesting its potential as a supplementary therapy for this condition. Dellinger et al. (2023) reported on a double-blind, placebo-controlled clinical trial involving 111 adults with NAFLD, which found that nicotinamide riboside and pterostilbene supplementation reduced liver enzyme levels and ceramide 14:0, indicating anti-inflammatory effects.
Safety studies have also been conducted. Majeed et al. (2023) performed a randomized, double-blind, placebo-controlled study with 60 healthy adults and found that Silbinol® (PME) at 200 mg/day was safe over two months with no adverse effects observed. However, the Riche trial (2014) noted a dose-dependent increase in LDL cholesterol at the highest dose (250mg twice daily), which warrants monitoring.
Overall, pterostilbene demonstrates promising benefits across cardiovascular health, cognitive function, and anti-inflammatory properties, supported by robust clinical trials.